<DOC>
	<DOC>NCT00686179</DOC>
	<brief_summary>The purpose of this study is to evaluate the effects on cardiac repolarisation of supratherapeutic doses of AZD3480 compared to placebo in healthy male volunteers, subgrouped as extensive metabolisers and poor metabolisers according to CYP2D6 metabolic capacity, using moxifloxacin as positive control.</brief_summary>
	<brief_title>Investigate the Effect on the QT/QTc Interval of Repeated and Escalating Doses of AZD3480 During 6 Days</brief_title>
	<detailed_description />
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>Participation in a previous study for genotyping for identification to be extensive or poor metaboliser (CYP2D6 enzyme) Physically and mentally healthy male volunteers History of clinically significant diseases or illness. Participation in another study the last 3 months Prescribed or nonprescribed medications from 3 weeks prior to first treatment day until followup except for paracetamol (max 1.5 g per day.)</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>TQT</keyword>
	<keyword>ECG</keyword>
	<keyword>QT</keyword>
	<keyword>QTc</keyword>
	<keyword>AZD3480</keyword>
	<keyword>ECG(QTc effects)</keyword>
</DOC>